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Introduction
Asbestos is a natural fibrosus mineral with many useful 
properties from the industrial point of view. It is extremely 
durable, resistant to most chemical reactions as well as 
fire and hot temperatures. Consequently, asbestos, mined 
for centuries, has been increasingly used for a variety of 
applications around the world, especially heavy industry 
(steelmaking, siderurgic and metallurgic implants, chemical, 
electrical, automotive industry, etc.) and construction 
activities. Worldwide commercial production of asbestos 
reached a peak of more than 5 million tons in the 1970s 
and WHO estimates that 125 million workers are exposed 
to asbestos (1). Many domestic tools or products are 
responsible for a non-occupational exposure to asbestos, 
too. Asbestos is nowadays banned in most developed 
countries, but there is a consistent part of the world where 
mine extraction, trade and use in manufacturing is still 
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allowed, such as Canada, Russia, China, Brazil. Due to its 
long bio-persistence, it continues to be responsible both 
for a number of benign and malignant diseases. Asbestosis, 
pleural plaques, diffuse pleural thickening, round atelectasis 
and bronchiectasis are the common benign asbestos-related 
lung diseases. Inhaled asbestos fibers cause a number of 
malignancies such as mesothelioma (pleural, pericardial, 
peritoneal), lung cancer, larynx cancer, ovarian cancer, and 
although with less extent of evidence, it has been associated 
to some gastro-intestinal cancers, too. However, among 
these cancers only malignant pleural mesothelioma (MPM) 
is demonstrably caused by asbestos at as high as more than 
80% cases, after a latency period of decades. This has 
oriented the scientific investigation toward the research 
on biomarkers potentially useful for preventive or clinical 
purposes, mainly targeting MPM. 
Biomarkers classification
According to the National Cancer Institute Dictionary of 
Cancer Terms, biomarkers are biological molecules found 
in blood, other body fluids, or tissues that are a sign of a 
normal or abnormal process, or of a condition or disease. 
Another highly referenced definition was expressed by 
Hulka and colleagues in the nineties (2): “cellular, biochemical 
or molecular alterations that are measurable in biological 
media such as human tissues, cells, or fluids.” Biological 
markers (biomarkers) lend themselves to a wide range 
of applications. They are currently used in both fields of 
prevention (biomarkers of exposure, risk prediction, etc.) 
and clinical investigation (biomarkers of early diagnosis, 
prognosis, treatment response, etc.) and potentially track 
all the steps from the exposure to an etiological factor to 
the complete evolution of a disease. The classification in 
“biomarker of exposure”, “effect” and “susceptibility” is well 
established. Under the category of “biomarkers of exposure” 
fall all those molecules, which provide information 
regarding the dose of the exposure, which in turn is usually 
related to the potential for adverse effects on health. 
“Biomarkers of effect” are biological indicators of 
the body’s response to exposure. They usually represent 
from early to late sub-clinical effects, as expression of the 
involvement in some pathogenic pathways. Most biomarkers 
studied to date belong to this category. They often 
result from the attempt to dose in blood those molecules 
responsible for the specific cancer histotype, sometimes 
even with no clear evidence of any pathogenic specific 
role. The majority of markers of diagnosis, early diagnosis, 
prognosis and response to treatment fall under this latter 
category. “Biomarkers of susceptibility” indicate subjects 
with increased tendency to get a health damage after having 
exposed to specific aetiological factors. They may be specific 
genetic fingerprints (i.e., defective glutathione S-transferase 
haplotype haplotype) as well as specific protein patterns 
often unveiling some individual metabolic deficiency. Of 
course, classification into these three categories serves 
much more for didactic than practical purposes, and some 
molecule’s roles may overlap. 
Preventive programs on asbestos exposed 
population
From a preventive point of view people at high risk for 
cancer can be targeted through two different approaches: 
screening programs and health medical surveillance.
In general, screening aims to diagnose cancer or its 
precursor lesions in apparently healthy, asymptomatic 
people by means of tests (e.g., fecal occult blood test for 
colon-rectum cancer), examinations (e.g., Pap test for 
cervical cancer), imaging (e.g., mammography for breast 
cancer) or other procedures that can be applied rapidly, and 
widely accessed by the target population. The diagnosis 
of asymptomatic early staging cancer is usually the unique 
objective of the entire program. On the contrary, with 
“health medical surveillance”, we refer to a system of 
ongoing different health checks with a wider range of 
scopes. In the case of asbestos workers objectives of follow-
up programs should be not only the early diagnosis of lung 
malignancies, but also the diagnosis of benign asbestos-
induced lung diseases as well as any other clinical (e.g., 
prompting smoking cessation, influenza and pneumococcus 
vaccination, etc.), medico-legal (e.g., compensation) or 
epidemiological purposes. According to the ATS guidelines, 
to identify the onset of benign thoracic asbestos-related 
diseases, people with a minimal 10-year long history of 
asbestos exposure even with no apparent disease, should 
undergo a preventive follow-up with chest films and 
pulmonary function respiratory tests every 3 to 5 years (3). 
Although many asbestos-exposed workers around the 
world have been periodically in the past and are currently 
followed-up by chest X-ray and computed tomography (CT) 
examinations, there still is inadequate evidence of any 
effectiveness in thoracic cancer diagnosis. So far, screening 
for thoracic malignancies using periodic chest X-ray 
or CT in exposed people was not recommended (3,4). 
High resolution computed or low-dose tomography has 
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been proposed only as second line diagnostic procedure 
whenever the chest film was altered. However, recent 
demonstration by the National Lung Screening Trial 
(NLST) (5) of a reduction in the mortality rate for lung 
cancer in high risk former or current smokers followed 
up with annual low-dose CT (LDCT), suggests that 
individuals who are at or above the risk threshold set 
for participation in the NLST, regardless the nature of 
the risk (either determined exclusively by asbestos or by 
the more than additional effect of combined exposure 
to asbestos and smoking),  might benefit  of being 
enrolled in dedicated follow-up programs (Helsinki 
criteria 2014) (6). Periodic protocol of radiologic exams 
should be set on a risk/benefit balance, considering 
both intrinsic risk for health caused by imaging and the 
underlying cancer risk due to asbestos exposure and possibly 
other factors (i.e., smoking habits). 
An explicative example of health surveillance applied to a 
high risk for asbestos exposure population was reported by 
Guglielmi et al. in 2012 (7), shown in Figure 1. This health 
surveillance protocol is based on a detailed asbestos-related 
work history data collection, aimed at a risk stratification, 
respiratory function tests, thoracic X-ray and/or LDCT. 
Along with these exams a research program for evaluating 
the role of some serum biomarkers is performed. The 
frequency of radiological exams and marker dosage may 
change according to the trend (positive or negative) of the 
previous clinical test. 
Updated research on biomarkers for MPM 
Mesothelin, one of the most investigated markers in the 
MPM, is a 40-kDa protein expressed at a low level by 
pleural, peritoneal, pericardial normal mesothelial cells. The 
term “soluble mesothelin-related peptides” (SMRP) refers 
to a number of similar proteins deriving from subsequent 
cleavages of cell-surface precursor. SMRP has been found 
to be able to discriminate between epithelioid MPM 
histotype (8), and controls with a high specificity (80–85%), 
though with less consistent sensitivity (60–90%) (9-11). 
Diagnostic performance of SMRP may be influenced by the 
prevalence of specific genetic polymorphisms within the 
MSLN gene. In fact, some variants both in the promoter (12) 
and in the 3' untranslated region (13) of the MSLN gene 
were found to be associated with high levels of SMRP in 
healthy subjects.
Careful interpretation, before the attribution of a 
diagnostic valence of SMRP values, is also suggested by the 
Figure 1 A possible approach to preventive health surveillance of workers previously exposed to asbestos. Pos, positive; Neg, negative; 
LDCT, low-dose computed tomography.
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evidence that some clinical conditions such as renal failure 
or hypertension (14), body mass index (15) may significantly 
affect diagnostic ability to differentiate MPM from healthy 
people. 
Testing 219 serum samples from 56 MPM patients, collected 
during their clinical follow-up, we demonstrated (16) that SMRP 
serum levels parallel (as well as vimentin) the disease status 
according to response therapy or disease progression (17). 
Nevertheless, the role of mesothelin in cancer as well as 
normal cells is not yet clear, even though some evidence was 
reported that it might promote tumor invasion (18). Recent 
studies highlight three mechanisms by which mesothelin 
might play a role in cancer progression. First, mesothelin 
may aid in the peritoneal implantation and metastasis 
of tumors through its interaction with mucin MUC16 
(also known as CA125) (19,20). Second, mesothelin may 
promote cancer cell survival and proliferation via the 
NF-κB signaling pathway (21). Finally, mesothelin 
expression promotes resistance to certain chemotherapy 
drugs such as TNF-α, paclitaxel, and a combination of 
platinum and cyclophosphamide (22). It is expressed mainly 
by MPM but also by pancreatic cancer, ovarian cancer or 
some breast and lung cancers (23). However, its cancer-
specific expression makes mesothelin a potential target for 
monoclonal antibody therapy. 
Osteopontin (OPN) is a glycoprotein over-expressed in 
several human neoplasms such as lung, breast and colon 
cancer (24). OPN modulates cell-matrix interactions; 
high levels correlate with tumor invasion, progression and 
metastasis. Mean plasma OPN values were significantly 
higher in MPM patients than in controls and patients 
suffering with benign respiratory disease (BRD), and no 
statistically significant difference was found comparing 
the mean value of controls and BRD groups. Moreover, 
neither clinical status nor smoking habit could affect the 
result of the OPN measurement (25). Unfortunately, use of 
OPN for diagnostic purpose in MPM is still controversial, 
since it has been validated in some studies (25,26) but not 
in others (27). A recent review on the diagnostic accuracy of 
serum OPN in discriminating MPM from controls showed 
that the pooled sensitivity and specificity were 57% and 
81%, respectively overall serum OPN (28) .
The megakaryocyte potentiating factor (MPF) is a 
31-kDa cytokine sharing with mesothelin the same coding 
gene (mesothelin gene MSLN). This gene codes for a 
71-kDa precursor protein, releasing, after a furin cleavage, 
both 40-kDa C-terminal mature mesothelin and the 31-kDa 
N-terminal mature MPF. MPF has been measured in blood 
samples with the aim to test its ability to diagnose MPM by 
different research groups (14,29-33), using different ELISA 
assays based either on commercial or home-produced pairs 
of monoclonal anti-MPF antibodies. Regardless differences 
in methods all the studies showed that MPF diagnostic 
performance is similar to SMRP, while the combination of 
the two biomarkers has given inconsistent results (14,33,34).
Recently a glycoprotein encoded by the EFEMP-1 gene, 
named Fibulin-3 was suggested as a promising diagnostic 
marker for MPM (35). Since this first publication, other 
research groups confirmed the ability of the molecule 
to discriminate MPM from controls, though the test 
performance was not reproduced as high as well. A recent 
meta-analysis conducted by Pei et al. (36), including six 
studies, 468 MPM patients and 664 controls, reported a 
pooled sensitivity of 62% at a specificity of 82% after the 
outlier-adjustment.
High mobility group box 1 (HMGB1) is a very interesting 
molecule with great potential for an application as a 
biomarker for diagnostic, prognostic purposes and as 
exposure biomarker as well. Yang et al. (37) showed that 
asbestos fibers induce HMBG1 translocation from the 
nucleus to the cytoplasm and into the extracellular milieu, 
which in turn is induces macrophages to secrete TNF-α, 
contributing to the inflammatory response involved 
into the asbestos carcinogenesis. Other studies provided 
further mechanisms of inflammatory response via Nalp3 
inflammasome activation and IL-1b secretion (38-40). 
The observation that the inhibition of HMGB1, either by 
monoclonal antibodies (41) or by ethyl pyruvate is able to 
suppress the malignant phenotype of cultured mesothelioma 
cells (42), supports a strategic role of this molecule in the 
tumor progression. Serum total HMBG1 (i.e., the sum 
of both acetylated and non-acetylated HMBG1) levels 
in MPM patients were found significantly higher than in 
asbestos either exposed or non-exposed individuals (37,43), 
supporting a role a diagnostic biomarker. Interestingly, 
total HMBG1 has also been suggested as a biomarker 
of exposure, since serum mean levels were significantly 
higher in asbestos exposed than non-exposed subjects 
with a high-performance accuracy [area under the curve 
(AUC): 95% CI] (43). Particularly high was the diagnostic 
accuracy showed by Napolitano et al. of the hyperacetylated 
HMBG1, which reached a 100% sensitivity, to make a 
mesothelioma diagnosis, among 22 cases and 20 healthy 
volunteers. These results are very promising though need 
confirmation with larger population. 
Most cases of MPM (up to 80–90%) are demonstrably 
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associated with either occupational or environmental 
exposure  to  a sbes to s  f ib re s  o r  o ther  e longa ted 
mineral particles, such as asbestiform erionite (44). 
Notwithstanding, multiple cases of MPM in the same 
family as well as sporadic MPM can occur in the absence 
of a previous exposure to carcinogenic mineral fibres. Testa 
et al. (45) discovered that germline mutations in BRCA1-
associated protein 1 (BAP1), inherited in an autosomal 
dominant manner, predispose to MPM. In experimental 
animals, BAP1 mutations increase the incidence of 
mesothelioma after exposure to asbestos at very low 
doses (46). BAP1 might drive to cancer development 
because of its role in cell-cycle progression and tumour 
suppressing activity (47,48). The MPM prevalence 
in experimental model raised up to >70% in BAP1-
mutant animals after asbestos exposure, in the face of 
a spontaneous rate of 2.2% in germinal mutant non-
exposed (49). These data suggest that germline BAP1 
mutations make individuals more susceptible to develop 
sporadic MPM and highly increase the asbestos-induced 
risk of pleural malignancy. In addition, germline BAP1 
mutations may be responsible for the almost anecdotic 
reports of MPM family clustering, as demonstrated 
in two high-risk mesothelioma families investigated 
in  US  (45 ) .  A  s tudy  pub l i shed  in  2013  showed 
a prevalence of somatic BAP1 mutations in 20% of the 
analysed MPM (50). These results were replicated 2 years 
later in 23% of MPM (51). Germline BAP1 mutation 
can be considered as “marker of susceptibility”, not only 
for MPM but also for the development of a spectrum 
of tumour types, including some skin tumours (atypical 
benign melanocytic lesions, cutaneous melanoma, basal 
cell carcinoma), uveal melanoma, and some other cancers 
of the central nervous system, kidney, lung and breast (49). 
Micro-RNAs (miRNAs) are, 20–25 nucleotides long, 
non-coding RNA molecules, which regulate gene expression 
pairing with complementary sites of the correspondent 
mRNAs (52). Each mRNA may target large number of genes, 
and they are involved in many different either physiologic 
(cell proliferation, differentiation, metabolism, senescence) 
or pathologic (cancer transformation, invasion, etc.) (53,54). 
So far, several miRNAs have been suggested as biomarkers 
for the diagnosis of different type of cancer, including MPM. 
Although, different authors demonstrated that dysregulated 
miRNA (both up- and downregulated), detected in both 
tissues and blood samples, discriminate MPM patients from 
health controls with significant accuracy. Busacca et al. (55) 
found miRNA-17-5p, miRNA-21, miRNA-29a, miRNA-30c, 
miRNA-30e-5p, miRNA-106, and miRNA-143 were 
differentially expressed in mesothelioma and mesothelial 
cultured cells. Unfortunately, following research did not 
reproduce a consistent miRNA signature neither in tissue 
nor in blood samples. After Santarelli et al. suggested 
miRNA126 as a blood diagnostic marker for MPM, the 
same research group confirmed this result (56) also in 
combination with other biomarkers (57). Bononi et al. in 
2016 proposed three circulating up-regulated microRNAs, 
i.e., miR-197-3p, miR-1281 and miR-32-3p as potential 
new MPM biomarkers (58). Weber et al. (59) found 
that the combination of circulating miR-132-3p with 
miR-126 improved the diagnostic performance of MPM, 
while miR-20b, miR-28-3p, and miR-146b-5p showed 
no statistically significant differences between asbestos-
exposed controls and mesothelioma patients. De Santi 
et al. confirmed, after a strong validation test, a significant 
differentially expression of miR-185, miR-197 and miR-
299 in MPM cases and identified a two-miRNA prognostic 
signature, composed by Let-7c-5p and miR-151a-5p (60).
Although results of studies based on the “miRNomic” 
approach are very intriguing they lack of sufficient 
overall consistency. In fact, probably because different 
microarray panels were tested, different miRNAs from 
time to time have been proposed. In addition, whenever 
the same miRNAs have been investigated, differences in 
methodologies, normalization process, biologic matrix 
for extraction (serum or plasma), have determined some 
limitations in their cross-comparison (56). Nonetheless, 
the available data indicate the probable future utility 
of miRNAs as biomarkers of prediction, diagnosis, 
prognosis and, based on in vitro experiment of oncogenic 
miRNA inhibition and tumor suppressive tumor miRNA 
substitution, of biomarker of treatment, too. 
Multiple biomarkers panels
The need for a reliable biomarker of early diagnosis of 
MPM has prompted the research around the world since in 
2003 when mesothelin was suggested as the first diagnostic 
biomarker by Robinson et al. in 2003 (61). From that time 
on several diagnostic biomarkers have been proposed. 
However, none of them is characterized by the necessary 
combination of sensitivity and specificity to legitimate a 
clinical and particularly effective preventive and translation. 
For this reason, some studies started to investigate the 
usefulness of combining different biomarkers chosen 
among most promising ones. One of the first evidence of 
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the goodness of this approach was provided by a study we 
published in 2011 demonstrating a significant improvement 
of diagnostic performance by combining serum mesothelin 
and plasma OPN dosage (62). In fact, the AUC value 
deriving from the combination of the two markers (0.873) 
was higher than the one deriving from each of them (0.795 
for OPN and 0.62 for SMPR). 
Very recently, we carried out a study, which through 
a preliminary paired genomic and proteomic approach 
(63,64) allowed us to test in the serum by the use of specific 
ELISA, a set of putative blood markers for the diagnosis 
of MPM. Each of these markers were singularly tested for 
their diagnostic performance as well as in combination 
with one or more of the other, using a logistic regression 
method (65). The population enrolled into this study was 
composed by 43 subjects previously exposed to asbestos 
and 27 epithelioid MPMs. The best result was given by 
the combination of six biomarkers: SMRP, plasma OPN, 
interluekin-6 (IL6), vimentin, desmin, hepatocyte growth 
factor (HGF). This panel reached at a best cut-off of 0.13 a 
specificity and a sensitivity of 85.7% and 100%, respectively. 
So, we concluded that the combination of multiple markers 
could be very useful rather than the use of single markers in 
the diagnosis of MPM.
Discussion
The extraordinary long latency along with the possibility 
of identifying very well-defined populations at high risk 
for cancer development, as asbestos is almost its unique 
aetiological factor, make MPM a paradigmatic tumor 
to test diagnostic, prognostic biomarkers. In addition, 
sensitive and specific biomarkers for MPM are urgently 
needed for screening of asbestos-exposed subjects, since 
early diagnosed patients may benefit a better survival 
through a more effective multimodality therapy (surgery 
combined with radiotherapy and chemotherapy) (66,67). 
Nevertheless, biomarkers for routinely early diagnosis 
and screening are not available yet. In fact, the SMRP, 
which is the most widely evaluated serum marker for early 
diagnosis of malignant mesothelioma, although quite 
specific, has showed a relatively poor sensitivity. As well, 
other biomarkers (e.g., OPN, MPF, Hyaluronic acid, etc.) 
on which attention was driven by most researchers lack 
adequate either specificity or sensitivity. Some very 
recently discovered putative mesothelioma biomarkers 
are very promising (e.g., Fibulin-3, HMGB, miRNAs), 
displaying a better diagnostic performance in comparison 
with more “traditional”, but need further confirmation. 
Notably, HMGB, if confirmed in larger population and 
other independent research groups, might be very useful 
also as marker of asbestos exposure. According to the 
2014 Helsinki Criteria for Diagnosis and Attribution, 
some of the studied biomarkers are promising but still 
need further confirmation through experimentation in 
larger population and/or in longitudinal screening of 
asbestos-exposed individuals rather than a single baseline 
assessment. Consistently with this point of view, the 
three Italian National Consensus on Mesothelioma, 
held in Bari in June 2015, stated that though at present 
the determination of circulating mesothelin is not 
recommended as a routinely screening tool, it should 
be encouraged within a research setting. Despite these 
statements some authors suggest that, especially those 
makers with particular high specificity, either when are 
unexpectedly increased or show an increasing trend 
within serial essays, may aid MPM driving to second level 
imaging procedures (68). Notwithstanding, it is important 
to underline the very promising results obtained from the 
combination of multiple markers for the ability to increase 
overall performance. However, there are some issues 
related both to studies design and to the interpretation of 
biomarkers values in cohorts of asbestos-exposed workers, 
that worth to be addressed. It is a matter of fact that an 
early diagnosis test should be characterized by the highest 
sensitivity and specificity rate as possible. However, it is 
extremely rare that a single biomarker can accomplish both 
these requirements, and sensitivity and specificity relate 
to the test accuracy, but of course, not the probability of 
the disease. As a general rule of epidemiology, the positive 
predictive value (PPV), that is the percentage of people 
positive to the test actually having the disease, will be 
inevitably low, in the case of rare target disease, even with 
highly accurate and precise tests. MPM is rare form of 
cancer in the general population, so it is no reasonable 
to perform generalized screening campaign for MPM 
diagnosis. The higher risk of MPM in individuals enrolled 
for screening, the better will be the PPV. Therefore, 
a correct classification of asbestos exposure is clearly a 
crucial point especially in auspicial prospective studied 
to be performed in order to verify the value of serial 
biomarkers measurement. Secondly, when tested in at 
high risk individuals, it is preferable to set up a cut-off 
point of putative early diagnosis biomarkers, favoring 
the specificity at the expense of sensitivity, in order to 
minimize the false positive rate and the consequent 
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psychological distress as well as the increase of unnecessary 
diagnostic examinations. Finally interpreting biomarkers 
values we should always take into account all the possible 
confounding factors (e.g., glomerular filtration, body mass 
index, specific genetic haplotype, etc.) and most credit 
has to be given to an increasing trend than to a single 
occasional increased value. Since MPM has a rapid onset 
with a 6 up to 12-month delay in diagnosis research on 
biomarkers of early diagnosis should be driven to the 
discovery of more manageable tests. In conclusion, the 
up-to-date research suggests that, along with a more 
consolidated prognostic and monitoring role, some blood 
biomarkers especially when combined in specific panel are 
very promising also in the field of prevention and further 
research is highly recommendable. 
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